All In Biotech

Drug Trial Radar · NCT07667322

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis

A Phase 1b Multicenter, Non-randomized, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Single Ascending Doses of a New Subcutaneous Formulation of Ocrelizumab in Patients With Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Dec 17, 2024

Primary completion

Sep 1, 2026

Study completion Aug 1, 2028

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the safety and tolerability of the ocrelizumab subcutaneous (SC) test formulation in participants with multiple sclerosis (MS). The study consists of two treatment phases: a dose-escalation and dose-continuation phase. Participants will receive single ascending doses of ocrelizumab SC during an initial dose-escalation phase, with the option to continue treatment with the selected dose of ocrelizumab SC in the dose-continuation phase.

Conditions

  • Multiple Sclerosis

Interventions

  • Ocrelizumab Co-formulated With rHuPH20Drug

    Participants will receive ocrelizumab co-formulated with rHuPH20, as a SC injection, per the schedule specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: Up to 168 weeks

Locations

12 sites in 4 countries. Site status is shown where the registry gives one.

  • Profound Research, LLC

    Carlsbad, California

  • Neurology Associates, PA

    Maitland, Florida

  • University of South Florida

    Tampa, Florida

  • Shepherd Center Inc.

    Atlanta, Georgia

  • John Hopkins University School of Medicine

    Baltimore, Maryland

  • Hope Neurology

    Knoxville, Tennessee

  • Instituto de Neurologia de Curitiba

    Curitiba, Paraná, Brazil

  • Centro de Pesquisas Clinicas

    São Paulo, São Paulo, Brazil

  • Centro de Investigacion Medico Biologico y Terapia Avanzada, S.C.

    Guadalajara, Jalisco, Mexico

  • Inovacion y Desarrollo en ciencias de la salud

    Mexico City, Mexico CITY (federal District), Mexico

  • Nottingham University Hospitals NHS Trust

    Nottingham, United Kingdom

  • Morriston Hospital

    Swansea, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.